Ambriz FR

Language: Spanish
References: 23
Page: 29-55
PDF size: 1210.95 Kb.

ABSTRACT

The Central Blood Bank is the unique blood center in Mexico than in hemophilia management has recognized by the World Federation of Hemophilia on its website: www.wfh.org, Montreal, Canada. Our programs of treatment were development gradually: as replacement therapy, the ambulatory outpatient treatment, the multidisciplinary approach; home therapy and/or prophylaxis treatment. It describes the history of our developments over the past 40 years and as we have had a role to have prompted the management of hemophilia in the country, as well as in the international context, we have made The XXIst International Congress of the World Federation of Hemophilia, Mexico 1994 «Togetherness makes it better» under the leadership of one of the legend of the hematology, Professor Pier M. Mannucci, and the academic participation of Professors as Carol K. Kasper and Raúl Ambriz. This Hemophilia Center has integrated services for hemophilia, no that there is in another blood bank of the country like: the site of reference in physical medicine for hemophilia, psychology and preventive medicine, as well as the laboratories of hemostasis, molecular biology and of regenerative medicine for support the diagnosis and treatment of the hemophiliac patients. In our area of influence the High Level Hospitals at the National Medical Center 21st Century and the Regional or Second Level General Hospitals, complete comprehensive treatment of hemophilia.

REFERENCES

1. Pizzuto J, Ambriz R, Reyna MP, Monrroy LM, Morales MR, Avilés A, Conte G, Enríquez R. Acquired von Willebrand’s syndrome during autoimmune disorder. Thromb Haemost 1980; 42: 1523-1528.

2. Ambriz-Fernández R, Avilés-Miranda A, Reyna-Fregoso MP, Ballesteros-Téllez L, Pizzuto-Chávez J. Utilidad de un perfil básico para la certeza diagnóstica en la hemofilia A. Gac Med Mex 1983; 119: 477-482.

3. Chávez-Vela JJ, Ambriz R, Pizzuto J, Paz Reyna M, Avilés A, Morales M, Herrera J, Sinco A. Deficiencia hereditaria del factor X de la coagulación. Estudio de diez casos de una familia en México. Rev Invest Clin 1983; 35: 309-314.

4. Ambriz FR, Reyna MP, Cruz ML, Avilés A, García MA, Morales PMR, Pizzuto J. Utilidad de los factores VIII: C y VIIIRAg en la búsqueda de portadoras en hemofilia clásica. Rev Invest Clin 1984; 36: 237-241.

5. Ambriz FR, Avilés MA, Reyna FMP, Ballesteros L, Pizzuto J. Enfermedad de von Willebrand. Informe de 60 casos de 24 familias en México. Rev Med IMSS 1984: 241-247.

6. Ambriz FR, Villaseñor A, Reyna MP, Pizzuto J, Guillén C. Deficiencia congénita combinada de los factores V y VII de la coagulación en una familia mexicana: Deficiencia Toledo-Tehuantepec, un nuevo trastorno. Arch Invest Med (Mex) 1985; 16: 59-70.

7. Ambriz FR, Vázquez CC, Guttin FE, Ruiz AGJ, Wilkins GA, Chávez SG, Pizzuto J. Hemoperitoneo masivo, deficiencia endógena de protombina y poliquistosis ovárica. Rev Gastroenterol Mex 1985: 50: 133-136.

8. Ambriz FR, Pizzuto J, Guillén C. Danazol in hemophilia. JAMA 1985; 254: 754.

9. Ambriz FR, Reyna FMP, Chávez SG, Farfán CJM, Pizzuto CHJ, Salamanca GF. Deficiencia del factor V (parahemofilia) en una familia mexicana. Primer informe de México. Rev Invest Clin 1985; 37: 241-244.

10. Ambriz FR, Reyna FMP, Pizzuto CJ, Rodríguez MH, Farfán CJM, Trueba CE, Collazo JJ. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia. Arch Invest Med 1985; 16: 225-235.

11. Rodríguez MH, Ambriz FR, Pizzuto CJ, Farfán CJM, Hernandez LMS, Guillén MC, Ramírez OG, Benitez AH. Tratamiento oportuno de la hemofilia clásica. Estudio del grupo cooperativo de hemofilia. Bol Med Hosp Infant Mex 1986; 43: 742-749.

12. Vallez de RM, Ruiz AA, Ruiz AGJ, Ambriz R. Prothrombin Mexico City, an asymptomatic autosomal dominant prothrombin variant. Am J Haematol 1987; 24: 229-240.

13. Ambriz FR, Rodríguez MH, Villanueva RM, Muñoz OR, Gacitua ZS. Artropatía hemofílica. Enfoques terapéuticos en la clínica de hemofilia. Gac Med Mex 1991; 127: 233-240.

14. Ketterling RP, Liu JZ, Liao D, Kasper CK, Ambriz R, Paredes R, Sommer S. Two novel factor IX mutations: incremental progress towards “saturation in vivo mutagenesis” of human promoter region. Hum Mol Genet 1995; 4: 769-770.

15. Throland EC, Weinshenker BG, Liu J-Z, Ketterling RP, Vielhaber EL, Kasper CK, Ambriz R, Paredes R, Sommer SS. Molecular epidemiology of factor IX germline mutations in mexican hispanics: pattern of mutation and potential founder effects. Thromb Haemostas 1995; 74: 1416-1422.

16. Sommer SS, Ketterling RP, Vielhaber E, Schaid DJ, Kasper CK, Phillips JA, Koerper MA, Kim H, Sexauer C, Gruppo R, Ambriz R, Paredes R. Germline origins in the human factor IX gene: frequent somatic mosaicism with G : C-A : T and increased mutations with advanced maternal age. Blood 1995; 86: 611.

17. Ketterling RP, Vielhaber E, Li X, Drost J, Schaid DJ, Kasper CK, Phillips JA 3rd, Koerper MA, Kim H, Sexauer C, Gruppo R, Ambriz R, Paredes R, Sommer SS. Germline origins in the human F9 gene: frequent G: C › A: T mosaicism and increased mutations with advanced maternal age. Human Genet 1999; 105: 629-640.

18. Ambriz R. Hemofilia. Retos en el manejo. Gac Med Mex 2000; 136: 127-128.

19. Ambriz R. Lineamientos generales para el tratamiento de la hemofilia. Hemofilia 2001: 151-166.

20. Ambriz R, Berges A, Benitez AH, Collazo JJ, Esparza FA, Martínez MC, Pompa GT, Quintana GS, Taboada C. Nuevos enfoques para la hemofilia. Las clínicas virtuales. Tópicos Selectos en Medicina Transfusional 2002: 255-261

21. Martínez MC et al. An economic model of haemophilia in Mexico. Haemophilia 2004; 10: 9-17.

22. Esparza FMA. Tratamiento preventivo y domiciliario de la hemofilia. Rev Méd IMSS 2005; 43: 139-141. Hemophilia 2004;10:9-17

23. IMSS, Programa Estratégico y Guías para el Manejo Integral del Paciente con Hemofilia en el Instituto Mexicano del Seguro Social, 2009: 1-52.